← Leaderboards
Sylvia B Smith
Medical College Of Georgia (Mcg)
$9,897,516
Attributed
$9,897,516
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $876.2K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,703,412 · 9
By mechanism
R01$8,312,911 · 3
P30$3,098,818 · 5
R21$291,683 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vision”
- Chanza Baytop · Westat, Inc.$271,217,917
- Edward W Maly · United Nations Children'S Fund$264,005,699
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Everette D Joseph · Howard University$243,972,016
Research focus
VisionFundingRetinaDiabetic RetinopathyGene ExpressionResearch PersonnelRetinalRetinal DiseasesGanglion CellReportingOxidative StressStructureMemberCell DeathIn VivoInstrumentationGlaucomaProteinsReceptorMediatingCollaborationsCenter Core GrantsCellsProductivity
Grant awards (42)
Module 1: Visual Function Assessment$196,332
P30 · FY2024 · EY · contact PI
Administrative Core$60,189
P30 · FY2024 · EY · contact PI
Module 1: Visual Function Assessment$196,786
P30 · FY2023 · EY · contact PI
Administrative Core$60,189
P30 · FY2023 · EY · contact PI
Center Core Grant for Vision Research$587,639
P30 · FY2022 · EY · contact PI
Module 1: Visual Function Assessment$199,404
P30 · FY2022 · EY · contact PI
Administrative Core$60,189
P30 · FY2022 · EY · contact PI
Center Core Grant for Vision Research$602,257
P30 · FY2021 · EY · contact PI
Module 1: Visual Function Assessment$199,404
P30 · FY2021 · EY · contact PI
Administrative Core$60,189
P30 · FY2021 · EY · contact PI
Center Core Grant for Vision Research$616,000
P30 · FY2020 · EY · contact PI
Module 1: Visual Function Assessment$200,051
P30 · FY2020 · EY · contact PI
Administrative Core$60,189
P30 · FY2020 · EY · contact PI
Sigma 1 Receptor: a novel therapeutic target for retinal degeneration$380,000
R01 · FY2019 · EY · contact PI
Sigma 1 Receptor: a novel therapeutic target for retinal degeneration$55,500
R01 · FY2019 · EY · contact PI
Sigma 1 Receptor: a novel therapeutic target for retinal degeneration$380,000
R01 · FY2018 · EY · contact PI
Sigma 1 Receptor: a novel therapeutic target for retinal degeneration$380,000
R01 · FY2017 · EY · contact PI
Role of homocysteine in retinal disease$375,000
R01 · FY2016 · EY · contact PI
Role of homocysteine in retinal disease$367,500
R01 · FY2015 · EY · contact PI
Role of homocysteine in retinal disease$367,500
R01 · FY2014 · EY · contact PI
Role of homocysteine in retinal disease$375,000
R01 · FY2013 · EY · contact PI
Diabetic retinopathy: sigma receptor 1 (??R1) as a novel therapeutic target.$342,000
R01 · FY2013 · EY · contact PI
Diabetic retinopathy: sigma receptor 1 (??R1) as a novel therapeutic target.$360,000
R01 · FY2012 · EY · contact PI
Diabetic retinopathy: sigma receptor 1 (??R1) as a novel therapeutic target.$357,800
R01 · FY2011 · EY · contact PI
Analysis of neural retina transport function$314,345
R01 · FY2011 · EY · contact PI
Diabetic retinopathy: sigma receptor 1 (??R1) as a novel therapeutic target.$372,500
R01 · FY2010 · EY · contact PI
Analysis of neural retina transport function$365,676
R01 · FY2010 · EY · contact PI
Analysis of neural retina transport function$369,315
R01 · FY2009 · EY · contact PI
Analysis of neural retina transport function$373,392
R01 · FY2008 · EY · contact PI
Analysis of neural retina transport function$330,750
R01 · FY2007 · EY · contact PI
Diabetic retinopathy: aR1 as a novel therapeutic target$312,431
R01 · FY2007 · EY · contact PI
Diabetic retinopathy: aR1 as a novel therapeutic target$314,190
R01 · FY2006 · EY · contact PI
Diabetic retinopathy: aR1 as a novel therapeutic target$321,750
R01 · FY2005 · EY
Diabetic retinopathy: aR1 as a novel therapeutic target$321,750
R01 · FY2004 · EY
RETINAL PIGMENT EPITHELIUM: VECTORIAL TRANSPORT FUNCTION$251,125
R01 · FY2003 · EY
RETINAL PIGMENT EPITHELIUM: VECTORIAL TRANSPORT FUNCTION$108,000
R01 · FY2003 · EY
RETINAL PIGMENT EPITHELIUM: VECTORIAL TRANSPORT FUNCTION$275,488
R01 · FY2002 · EY
RETINAL PIGMENT EPITHELIUM: VECTORIAL TRANSPORT FUNCTION$283,131
R01 · FY2001 · EY
SIGMA LIGANDS:PROTECTION OF DIABETES-INDUCED RETINOPATHY$147,997
R21 · FY2001 · EY
RETINAL PIGMENT EPITHELIUM--VECTORIAL TRANSPORT FUNCTION$7,643
R01 · FY2001 · EY
RETINAL PIGMENT EPITHELIUM--VECTORIAL TRANSPORT FUNCTION$251,125
R01 · FY2000 · EY
SIGMA LIGAND--PROTECTION OF DIABETES INDUCED RETINOPATHY$143,686
R21 · FY2000 · EY